ABLYNX ANNOUNCES NEW COMPELLING RESULTS ON OZORALIZUMAB (ATN-103) IN RHEUMATOID ARTHRITIS
(Thomson Reuters ONE) -
* Additional Phase II data (ACR20 84%; DAS28 remission 38%) demonstrates that
ozoralizumab could have an important competitive and differentiated position
in the $24 billion TNFa market
* Data from the open-label study suggest that ozoralizumab enables
individualised treatment, a real breakthrough in TNFa therapy, which could
prove beneficial to patients and minimise the treatment cost
* Immunogenicity did not affect the efficacy of ozoralizumab, while it is
known to have a big impact on the efficacy of Humira®, the world's biggest
selling anti-TNFa drug
Results will be discussed during a webcast press conference presentation
today at 14h CET, 8 am EST
Click here to register, call number +32 (0)2 789 21 26
GHENT, Belgium, 25 June 2012 - Ablynx [Euronext Brussels: ABLX], today announced
that its anti-TNFa Nanobody, ozoralizumab (ATN-103), for the treatment of
inflammatory diseases, showed excellent safety and efficacy results in the 48-
week open-label extension (OLE) study of the worldwide and Japanese Phase II
trials in the treatment of patients with Rheumatoid Arthritis (RA) who have an
insufficient response to methotrexate alone.
Dr Edwin Moses, Chairman and CEO of Ablynx, commented:
"We always believed in this programme and now the data from this long-term study
have even positively surprised us. We now have extensive efficacy data that are
potentially as good, if not better, than other commercially available anti-TNFa
products (and this is a $24 billion market) and, in terms of immunogenicity, an
unexpected and potentially major advantage over Humira®, the world's biggest
selling anti-TNFa and any of its biosimilar competitors that may be launched in
the future. We believe that we now have the components of a much stronger and
differentiating licensing package than we had previously."
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has over 25 programmes in the pipeline and seven Nanobodies are at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies, including Boehringer
Ingelheim, Merck Serono, and Novartis. The Company is headquartered in Ghent,
Belgium. More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (#AblynxABLX), LinkedIn and Facebook
M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx(at)mcomgroup.com
Complete version of the press release:
http://hugin.info/137912/R/1621722/518240.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1621722]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.06.2012 - 01:31 Uhr
Sprache: Deutsch
News-ID 1127107
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Ghent
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES NEW COMPELLING RESULTS ON OZORALIZUMAB (ATN-103) IN RHEUMATOID ARTHRITIS
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
